Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today collaborative presentations at the 67th American Society of Hematology Annual Meeting and Exposition
(Financial Post, 2025-12-06T13:08:33Z)